Mene Pangalos (AstraZeneca via YouTube)

As­traZeneca says its $200M cash bet on Io­n­is’ AT­TR drug is pay­ing off — with PhI­II da­ta set­ting up FDA fil­ing

When As­traZeneca wa­gered $200 mil­lion in cash up­front to bring in Io­n­is’ an­ti­sense can­di­date for hered­i­tary transthyretin-me­di­at­ed amy­loid polyneu­ropa­thy (AT­TRv-PN), it was not shy about in­tro­duc­ing a po­ten­tial­ly best-in-class drug in a space that, de­spite treat­ments from Al­ny­lam, Pfiz­er and Io­n­is it­self, still of­fers lim­it­ed op­tions.

It now has the late-stage da­ta to back up that claim — al­though it’s hold­ing the num­bers back.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.